Boston Oncology

Privately held: no public share price · United States

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
CDK2/4/6Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
ALK / ROS1Small molecule
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 June 2025Filing acceptedXZP-3287NMPA accepts bireociclib NDA for a third indication
CN, NMPA · Sihuan Pharmaceutical Holdings Group · Source ↗
2 May 2024Filing acceptedXZP-3621NMPA accepts NDA for dexitinib (XZP-3621)
CN, NMPA · Sihuan Pharmaceutical Holdings Group Ltd. · Source ↗

Financial reports

No financial reports recorded.